The International Journal of Neuropsychopharmacology
September 1, 2026
Marco Di Nicola, M Pepe, Giovanni Martinotti
Abstract Background Treatment-resistant depression (TRD) represents a major clinical challenge and is associated with substantial symptom burden, functional impairment, and poor prognosis. Beyond traditional monoaminergic models, converging evidence indicates that dysfunction of the glutamatergic system plays a central role in the pathophysiology of TRD, contributing to impaired neuroplasticity...
The International Journal of Neuropsychopharmacology
September 1, 2026
A Nunes, J E Cunningham, B Leden et al.
Abstract Background Use of intravenous ketamine or intranasal esketamine for depression is frequently limited due to resource requirements and cost. Alternative treatment models have used oral, sublingual or intranasal racemic ketamine, but optimal doses and frequency of administration remain unclear. Dosing modelled from the standard 0.5-1.0mg/kg twice weekly IV ketamine result in transient...
The International Journal of Neuropsychopharmacology
September 1, 2026
S Makhoul, N Abdulameer
Abstract Background Esketamine intranasal spray is FDA-approved for treatment-resistant depression (TRD), but it is not licensed for use in bipolar disorder due to the risk of antidepressants inducing manic or hypomanic episodes. To date, there is limited data on the use of intranasal esketamine in bipolar disorder, and no previous reports of using esketamine as an add-on treatment in patients...
The International Journal of Neuropsychopharmacology
September 1, 2026
Amel Bouloufa, Sarah Delcourte, Renaud Rovera et al.
Abstract Background Recent clinical findings have highlighted the therapeutic potential of serotonergic psychedelics, including lysergic acid diethylamide (LSD), in the treatment of affective disorders. Despite these advances, the mechanisms driving their beneficial effects remain partially understood. Aims & Objectives This study sought to assess the prophylactic effects of LSD in rodent...
The International Journal of Neuropsychopharmacology
September 1, 2026
Abstract Background Antidepressant effects of ketamine and esketamine are short lived, often lasting only weeks after multiple treatments. With that in mind, it has been considered addition of psychotherapy may enhance outcomes. One approach, knows as Ketamine Assisted Psychotherapy (KAP) focuses on "integration " of the dissociative experience induced by ketamine, and suggests this may produce...
The International Journal of Neuropsychopharmacology
September 1, 2026
K Kusudo, K Yonezawa, Sota Tomiyama et al.
Abstract Background Psilocybin, a prodrug metabolized to psilocin, a serotonin 2A receptor agonist, has reemerged as a promising therapeutic option for treatment-resistant depression (TRD). Clinical trials conducted mainly in North America and Europe have demonstrated that psilocybin administered with psychological support can produce rapid and sustained antidepressant effects with favorable...
The International Journal of Neuropsychopharmacology
September 1, 2026
K Yonezawa, K Kusudo, Sota Tomiyama et al.
Abstract Background Despite recent advances in the treatment of major depression, approximately 30% of patients show insufficient improvement with conventional antidepressants, a condition commonly referred to as treatment-resistant depression (TRD). Psilocybin is a classic psychedelic compound that has received renewed attention as a promising therapeutic candidate for TRD. Clinical trials...
The International Journal of Neuropsychopharmacology
September 1, 2026
Abstract Background Depressive disorders affect approximately 280 million people worldwide, with many patients finding existing treatments ineffective or limited by adverse effects. Growing evidence from community microdosing reports suggests that psychedelic therapies may help alleviate depressive symptoms. Among these, lysergic acid diethylamide (LSD) microdosing has shown particular promise...
Cureus
September 2026
Hemachandran Ravikumar, Suresh Sathyanarayanan
Background Psychological stress contributes to mental health symptoms and cardiovascular risk through pathways involving anxiety, depression, cortisol secretion, autonomic dysregulation, and elevated blood pressure. Sound-based meditation is a nonpharmacological approach that may support stress management, but randomized controlled trial evidence remains limited. Objective The objective was to...
Journal of managed care & specialty pharmacy
September 2026
Bridget Flavin, Gary Small, Charles Dragovich et al.
Treatment-resistant depression (TRD) is a subset of major depressive disorder (MDD) most commonly defined as failure to respond to 2 or more antidepressant regimens despite adequate dose, duration, and adherence to treatment. The burden of TRD impacts individuals, families, and society, with outcomes such as decreased health-related quality of life and increased health care utilization and...